Zydus Lifesciences gets USFDA nod to market generic drugs

Zydus Lifesciences has won regulatory clearance in the United States to launch generic Ivermectin and Dapsone tablets. Used to treat parasitic worm infections and leprosy, the approval signals progress in the company's US growth strategy and broad...

By PTI | Feb 28, 2026, 04.48 PM IST

New Delhi: Zydus Lifesciences on Saturday said it has received approval from the US health regulator to market generic anti-parasitic and leprosy medications.

The company has received final approvals from the US Food and Drug Administration (USFDA) for Ivermectin Tablets (3 mg) and Dapsone Tablets ( 25 mg and 100 mg), the Ahmedabad-based drug said in a statement.

Ivermectin tablets are prescription anti-parasitic medications primarily indicated for treating parasitic worm infections in humans, specifically intestinal strongyloidiasis and onchocerciasis.

Dapsone tablets are indicated for the treatment of leprosy and dermatitis herpetiformis.

It acts as an anti-infective and antibacterial agent and is used to control skin lesions in dermatitis herpetiformis and for leprosy.

Start a SIP with as low as ₹500 with ET Money App!